Vir Biotechnology, Inc.
VIR
Positions held
Your positionsVIR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Vir Biotechnology is positioned well in the biotechnology sector, focusing on innovative treatments that address unmet medical needs, which can lead to significant market opportunities.
- In Q2 2026, Vir achieved a gross margin of 100%, indicating strong product profitability.
- The company has a strong buy recommendation with a target mean price of $20.78, reflecting investor confidence in its growth potential.
- Despite its potential, Vir Biotechnology faces challenges with a high debt-to-equity ratio of 9.49, which may hinder financial stability.
- In 2025, the company reported a net income loss of $437.99 million, highlighting ongoing financial struggles.
- The operating margin has been negative, with a significant drop to -720.85% in 2025, raising concerns about operational efficiency.
Fundamentals
| Market cap | $1.88B | Enterprise value | $1.44B | Trailing P/E | — | Forward P/E | -4.47 |
| PEG | — | Price / book | 2.21 | Beta | 1.59 | Dividend yield | 0.00% |
| Revenue growth | 195.8% | Earnings growth | — | Gross margin | -59.4% | Operating margin | 30.7% |
| Profit margin | -83.0% | ROE | -26.1% | ROA | -14.5% | Debt / equity | 0.09 |
| Current ratio | 6.04 | Free cash flow | -$38.89M | Analyst recommendation | strong_buy | Mean target | $21.00 |
| 52w high | $11.94 | 52w low | $4.82 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $239M | -$0.0M | $63.8M | -$0.1M | $1.0M | — |
| Op margin | 30.7% | 322658.5% | -75.2% | 266835.4% | -11502.3% | — |
| Net income | $80.1M | -$126M | -$42.9M | -$163M | -$111M | — |
| Gross margin | 100.0% | — | 100.0% | 83.1% | 98.9% | — |
| Gross profit | $239M | — | $63.7M | -$0.1M | $1.0M | $1.8M |
| Operating income | $73.5M | -$132M | -$47.9M | -$173M | -$119M | — |
- Gross margin 100% (was 100% prior quarter).
- Operating margin compressed to 30.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $66.5M | $63.7M | $39.5M | $1.6B |
| Op margin | -720.9% | -866.7% | -1698.3% | 52.7% |
| Net income | -$438M | -$522M | -$615M | $516M |
| Gross margin | 100.0% | 98.7% | 93.0% | 90.7% |
| Gross profit | $66.5M | $62.9M | $36.7M | $1.4B |
| Operating income | -$480M | -$552M | -$671M | $833M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer
2026-10-08 · How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment Narrative
2026-10-07 · Vir Biotechnology Appoints David Liu as Chief Medical Officer
2026-10-01 · Vir Biotechnology Names Aziz Sawaf as CFO
2026-10-01 · Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
2026-08-31 · Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-13 · Olema Pharmaceuticals Names Jason O'Byrne CFO
2026-08-12 · Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
2026-08-06 · Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary
2026-08-06 · Vir Biotechnology Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns